Hubei Goto Biopharm Co.,Ltd.

Total Valuation

Hubei Goto Biopharm Co.,Ltd. carries a market capitalization of 3.39B, placing it among publicly traded companies globally. Its enterprise value stands at 3.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Hubei Goto Biopharm Co.,Ltd. currently has 115.28M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 3.28, and the price-to-book ratio stands at 5.02.

Enterprise Valuation

On an enterprise value basis, Hubei Goto Biopharm Co.,Ltd. trades at an EV/EBITDA multiple of 248.45 and an EV/FCF ratio of 11.45. The EV/Sales ratio of 5.23 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 248.45 provides insight into valuation relative to core operating earnings.

Financial Position

Hubei Goto Biopharm Co.,Ltd. maintains a current ratio of 1.04, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 123.00, indicating elevated leverage, while an interest coverage ratio of 0.33 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Hubei Goto Biopharm Co.,Ltd.'s stock has gained approximately 56.49627% over the past 52 weeks. The 50-day moving average sits at 26.98, while the 200-day moving average is 22.71.

Income Statement

Over the trailing twelve months, Hubei Goto Biopharm Co.,Ltd. generated 605.17M in revenue and converted that into -33.63M in net income, yielding earnings per share of -0.36. EBITDA reached 12.74M, while operating income came in at 12.74M.

Balance Sheet

Hubei Goto Biopharm Co.,Ltd. holds 133.83M in cash and equivalents against 1.23B in total debt, resulting in a net debt position of 1.05B. Total book value stands at 394.94M, with working capital of 32.84M providing operational flexibility.

Cash Flow

After subtracting -249.90M in capital expenditures, free cash flow totaled -249.90M - equivalent to -2.31 per share.

Margins

Hubei Goto Biopharm Co.,Ltd. operates with a gross margin of 21.61, reflecting its pricing power and cost economics. The operating margin of 2.10 and net profit margin of -5.56 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -59.82 indicates the proportion of earnings distributed to shareholders.

Scores

Hubei Goto Biopharm Co.,Ltd. posts an Altman Z-Score of 0.99, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.